Adicet Bio Files Routine 8-K, Confirms Nasdaq Listing

Ticker: ACET · Form: 8-K · Filed: Jan 16, 2024 · CIK: 1720580

Adicet Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyAdicet Bio, Inc. (ACET)
Form Type8-K
Filed DateJan 16, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, corporate-governance, compliance

TL;DR

**Adicet Bio filed a standard 8-K, confirming its Nasdaq listing and regulatory compliance.**

AI Summary

Adicet Bio, Inc. filed an 8-K on January 16, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on The Nasdaq Global Market under the ticker ACET. This filing, while routine, indicates that Adicet Bio is maintaining its compliance with SEC regulations. For investors, this matters because it signals ongoing operational transparency and adherence to listing requirements, which are foundational for investor confidence in the company's governance and market presence.

Why It Matters

This filing confirms Adicet Bio's continued compliance with SEC reporting requirements and its listing on The Nasdaq Global Market, which is crucial for maintaining investor trust and market liquidity.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information that would introduce significant risk.

Analyst Insight

A smart investor would view this as a routine compliance filing, indicating no immediate need for action but reinforcing the company's adherence to regulatory standards. It's a non-event for short-term trading but positive for long-term confidence in governance.

Key Numbers

  • $0.0001 — Par Value per Share (The par value of Adicet Bio's Common Stock.)

Key Players & Entities

  • Adicet Bio, Inc. (company) — the registrant filing the 8-K
  • The Nasdaq Global Market (company) — the exchange where Adicet Bio's common stock is registered
  • ACET (company) — the trading symbol for Adicet Bio's common stock
  • $0.0001 (dollar_amount) — par value per share of common stock
  • January 16, 2024 (date) — date of earliest event reported and filing date

FAQ

What is the primary purpose of Adicet Bio, Inc.'s 8-K filing dated January 16, 2024?

The primary purpose of Adicet Bio, Inc.'s 8-K filing on January 16, 2024, is to disclose general corporate information under Regulation FD Disclosure and Financial Statements and Exhibits, confirming its status and listing details as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

On which stock exchange is Adicet Bio, Inc.'s common stock registered?

Adicet Bio, Inc.'s common stock, with a par value of $0.0001 per share, is registered on The Nasdaq Global Market under the trading symbol ACET.

What is the trading symbol for Adicet Bio, Inc.?

The trading symbol for Adicet Bio, Inc.'s common stock is ACET, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported in this 8-K filing is January 16, 2024, as explicitly stated under 'Date of Report (Date of earliest event reported): January 16, 2024'.

What is Adicet Bio, Inc.'s business address as listed in the filing?

Adicet Bio, Inc.'s business address is 200 Berkeley Street, 19th Floor, Boston, Massachusetts, 02116, according to the 'BUSINESS ADDRESS' section of the filing.

Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-01-16 07:01:43

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 16, 2024, Adicet Bio, Inc. (the “Company”) posted to the “Presentations & Events” section of the Company’s website at investor.adicetbio.com an updated corporate presentation (the “Corporate Presentation”). A copy of the Corporate Presentation is furnished herewith as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits Exhibit No. Description 99.1 Adicet Bio, Inc. Corporate Presentation, dated January 16, 2024, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADICET BIO, INC. Date: January 16, 2024 By: /s/ Nick Harvey Name: Title: Nick Harvey Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.